Quote:

---

So it's a bit counter-intuitive to increase IL-2 unless you also downregulate Tregs.

---

Apparently Medicenna is trying to do just that with MDNA11, an IL-2 Superkine that has enhanced binding to IL-2Rbeta and no IL-2Ralpha binding. They are running a Phase 1/2 trial and show increased CD8 T cells with no noticable change in Tregs. They seemingly have a CR in a MSI-H PDAC patient. The trial includes a combo therapy with Pembro as they have a collaboration with Merck.

https://ir.medicenna.com/static-files/6c3ac05...284fa6fcd4